Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 17/20 | 1.00 |
| ▸ | PRKCB | P05771 | 10/20 | 0.77 |
| ▸ | PRKCA | P17252 | 5/20 | 0.76 |
| ▸ | PRKCG | P05129 | 3/20 | 0.76 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.63 |
| ▸ | IDH1 | O75874 | 1/20 | 0.61 |
| ▸ | CCNB2 | O95067 | 2/20 | 0.61 |
| ▸ | CDK1 | P06493 | 2/20 | 0.61 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.61 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.61 |
| ▸ | CDK2 | P24941 | 2/20 | 0.61 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.61 |
| ▸ | CCNB3 | Q8WWL7 | 2/20 | 0.61 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL462891 | 0.89 | GSK3B (1.00) | GSK3BPRKCBPRKCAPRKCGIDH1 | |
| SCHEMBL2984397 | 0.88 | GSK3B (0.82) | GSK3BPRKCBPRKCAPRKCGIDH1 | |
| SCHEMBL2985656 | 0.87 | GSK3B (1.00) | GSK3BPRKCBPRKCAPRKCGIDH1 | |
| SCHEMBL2982248 | 0.87 | GSK3B (0.76) | GSK3BPRKCBPRKCAPRKCGIDH1 | |
| SCHEMBL1128129 | 0.87 | GSK3B (0.76) | GSK3BPRKCBPRKCAPRKCGIDH1 | |
| SCHEMBL2983502 | 0.86 | GSK3B (1.00) | GSK3BPRKCBPRKCAPRKCGIDH1 | |
| SCHEMBL2982364 | 0.86 | GSK3B (1.00) | GSK3BPRKCBPRKCAPRKCGCAMK2D | |
| SCHEMBL2972351 | 0.86 | GSK3B (0.75) | GSK3BPRKCBPRKCAPRKCGIDH1 | |
| SCHEMBL2981051 | 0.86 | GSK3B (0.75) | GSK3BPRKCBPRKCAPRKCGIDH1 | |
| SCHEMBL13204161 | 0.86 | GSK3B (0.75) | GSK3BPRKCBPRKCAPRKCGIDH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2664669-B1 | TREATMENT OF PLURIPOTENT CELLS | JANSSEN BIOTECH INC (US) | 2017-12-27 | — | — | EP | disclosed |
| US-9845460-B2 | Treatment of pluripotent cells | JANSSEN BIOTECH, INC. (US) | 2017-12-19 | — | — | US | disclosed |
| US-20140080210-A1 | Treatment of Pluripotent Cells | JANSSEN BIOTECH, INC. (US) | 2014-03-20 | — | — | US | disclosed |
| US-8623648-B2 | Treatment of pluripotent cells | JANSSEN BIOTECH, INC. (US) | 2014-01-07 | — | — | US | disclosed |
| EP-2664669-A1 | Treatment of pluripotent cells | Janssen Biotech, Inc. (US) | 2013-11-20 | — | — | EP | disclosed |
| US-20090325293-A1 | TREATMENT OF PLURIPOTENT CELLS | JANSSEN BIOTECH, INC. | 2009-12-31 | — | — | US | disclosed |
| EP-1900738-A2 | Substituted pyrroline kinase inhibitors | Janssen Pharmaceutica, N.V. (BE) | 2008-03-19 | — | — | EP | disclosed |
| EP-1506192-B1 | SUBSTITUTED PYRROLINE KINASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2008-02-27 | — | — | EP | disclosed |